Firebrick Pharma (ASX:FRE) has expanded its Nasodine product range, announcing the manufacture of Nasodine Throat Spray, its first new product since the successful launch of Nasodine Nasal Spray in Singapore in 2024.
The new 1 per cent povidone-iodine formulation provides a convenient sore throat treatment in spray form, designed to target the affected area directly and eliminate the need to gargle or spit out unused solution. The low-volume spray also avoids the staining and inconvenience often associated with traditional throat gargles.
Firebrick has received a permit from the Therapeutic Goods Administration (TGA) allowing the export of the product from Australia, with manufacturing set to begin in partnership with Probiotec. The first batch is expected to be released for export in November 2025, with an initial launch in Singapore, where regulatory approval is not required for antiseptic products.
Firebrick’s Singapore-based licensing partner, Innorini Life Sciences, plans to begin marketing the product to hospitals and doctors from December 2025, ahead of a wider retail release in mid-2026.
Nasodine Throat Spray represents the next stage in Firebrick’s expansion of its povidone-iodine product portfolio, with further formulations expected to follow. The new product complements Nasodine Nasal Spray, which has already been launched in the United States, Singapore, Fiji and Brunei.
Each 25mL bottle of Nasodine Throat Spray contains a ready-to-use formulation with a precision nozzle for controlled application. The product will be made available in Singapore from December via nasodine-sg.com.